Protocol Ledger

NCT06793371 · Phase II · RECRUITING

AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF

Interventional Phase II clinical trial protocol NCT06793371 sponsored by Cytokinetics in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-02-06 Enrollment: 60 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06793371
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)60 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06793371
Protocol FieldVerified Registry Value
NCT IdentifierNCT06793371
Consolidated Lead SponsorCytokinetics
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment60 participants (ESTIMATED)
Registered Start Date2025-02-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06793371
Hospital Research SiteLocationSite Profile
UCSF Medical Center and Helen Diller Cancer CenterSan Francisco, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI